The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.

por Xiaohui Zeng, Jonathan Karnon, Siying Wang, Bin Wu, Xiaomin Wan, Liubao Peng
Publicado 2012

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.

por Qiao Liu, Chongqing Tan, Lidan Yi, Xiaomin Wan, Liubao Peng, Jianhe Li, Xia Luo, Xiaohui Zeng
Publicado 2021

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer

por Qiao Liu, Chongqing Tan, Lidan Yi, Xiaomin Wan, Liubao Peng, Jianhe Li, Xia Luo, Xiaohui Zeng
Publicado 2021

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy

por Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan, Chongqing Tan
Publicado 2021